ANNA STEĆ

Effect of renalase (*RNLS*) gene polymorphisms (rs1088700 and rs2576178) on plasma RNLS level in hemodialyzed patients affected by arterial hypertension and coronary artery disease

Abstract

Introduction. We have previously reported that rs10887800 and rs2576178 renalase (*RNLS*) single nucleotide polymorphisms (SNPs) are associated with the susceptibility to arterial hypertension (HY) and coronary artery disease (CAD) in hemodialyzed patients (HD). However, the underlying mechanism of this link remains undefined.

Aim. In the present study we examine the influence of above-mentioned *RNLS* gene variants on plasma renalase level in subgroups of HD patients affected by HY and CAD.

Material and methods. In total, 309 hemodialyzed patients participated in the study (157 males and 152 females, mean age 64.1±14.10 years). Rs10887800 and rs2576178 *RNLS* gene polymorphisms were genotyped using PCR-RFLP method. Plasma RNLS level was assessed by ELISA (USCN Life Science Inc., Wuhan, China). The data were analyzed using SPSS Statistics 23.

Results. Regarding rs10887800 polymorphism, hypertensive AA homozygotes had significantly lower plasma RNLS level (28.93±9.94 µg/mL) compared to AG (34.06±12.79 µg/mL) and GG carriers (36.54±12.01 µg/mL), $p=0.002$. Among CAD patients no differences in plasma RNLS concentrations between rs10887800AA, AG and GG carriers were observed (31.52±10.95 µg/mL, 34.75±13.37 µg/mL, 34.44±13.10 µg/mL, respectively), $p=0.615$. For the rs2576178 variant, both HY and CAD participants did not differ in terms of plasma RNLS levels with regard to the particular genotypes, $p>0.050$.

Conclusion. Obtained results extend our previous findings and indicate for the first time that rs10887800 *RNLS* gene variant modifies the level of plasma RNLS in hemodialyzed patients with HY but not in those with CAD. The study provides, thus, a new insight into the potential mechanisms through which *RNLS* gene variants modulate the risk of cardiovascular diseases among patients with end-stage kidney disease.

Keywords: cardiovascular abnormalities, renal dialysis, polymorphism, genetics.

DOI: 10.1515/pjph-2017-0031

INTRODUCTION

Patients with end stage kidney disease (ESKD) are at heightened risk of cardiovascular diseases (CVDs), among which coronary artery disease (CAD) is the most common (39% of all CVDs) [1]. The prevalence of arterial hypertension (HY) is about 90% at the beginning of renal replacement therapy (RRT) [2]. Compared with age-matched general population, mortality rate in dialysis patients is 10-20-fold higher and 50% of such deaths are related to CAD [3]. High prevalence of well-known cardiovascular risk factors (CVRFs) does not explain such a high CVD burden in uremic patients [4]. Thus, identification of a novel CVRF is crucial for better risk prediction and cardiac mortality prevention in this population.

Human renalase (RNLS), also called MAO-C, is suggested to be the missing link between heart and kidney diseases. RNLS is a FAD-dependent amine oxidase secreted into blood mainly by kidneys and degrades circulating catecholamines. RNLS is considered to play a role in the regulation of sympathetic tone, blood pressure and cardiac function [5].

RNLS gene is located on chromosome 10q23.31, spans 311 kb in length and encodes 16 exons. In our recent studies single

nucleotide polymorphisms (SNPs) in *RNLS* were associated with susceptibility to CVDs in hemodialyzed population. The G allele carriers of rs10887800 and rs2576178 SNPs had an increased risk of HY, whereas rs10887800GG genotype was related to CAD [6,7]. However, the underlying mechanism involved in this relationship remains undefined.

AIM

Therefore, the aim of the present study is to extend our previous findings by evaluating the effects of rs10887800 and rs2576178 *RNLS* SNPs on plasma renalase level in subsets of HD patients affected by HY and CAD. Additionally, to clarify the functional importance of renalase, the relationship between RNLS and selected CVRFs will be investigated.

MATERIAL AND METHODS

The study was conducted from January 2012 to December 2013 and involved 309 Caucasian hemodialyzed participants (157 males, 152 females, mean age 64.1±14.1 years) from 5 dialysis units in eastern Poland. All patients were on standard

bicarbonate dialysis (SBD). Diabetes mellitus was the most common cause of ESRD (23%). For the purpose of the study participants were classified into 4 subsets based on the presence (HY+, n=259) or absence (HY-, n=50) of HY and the presence (CAD+, n=107) or absence (CAD-, n= 202) of CAD. According to K/DOQI guidelines, HY was defined as systolic blood pressure (SBP) of ≥ 140 mmHg and/or a diastolic (DBP) of ≥ 90 mmHg and/or history of current antihypertensive treatment [8]. The diagnosis of CAD was based on the criteria of the European Society of Cardiology (ESC). The exclusion criterium was the presence of other heart diseases such as cardiomyopathy, pericarditis or aortic stenosis. Clinical, demographic and laboratory data were collected on the basis of medical interview, physical examination and patients' medical records. The arithmetic means of predialysis, systolic and diastolic BP, recorded for 2 weeks, were used for the analysis. Hemodialysis adequacy was assessed by a calculator, which uses the Daugirdas II equation formula for single pool Kt/V for urea (spKt/Vurea). The presence of residual renal function (RRF) was defined as the urine amount above 100 ml/day. The results of plasma RNLS level, genotype distribution and allele frequencies of rs10887800 and rs2576178 RNLS SNPs were taken from our previous studies [7,9]. All participants signed an Informed Consent Form. The study protocol was approved by the Bioethical Board of the Medical University of Lublin (No. KE-0254/154/2013).

Assays

Blood samples were drawn from the venous part of the vascular access at the beginning of hemodialysis session. Renalase concentrations were measured by commercially available ELISA kit from USCN Life Science Inc. (Wuhan, China).

Investigation of rs10887800 and rs2576178 renalase gene polymorphisms

Human genomic DNA was derived from peripheral blood leucocytes, prepared by a standard procedure and stored at -70°C before use. SNPs were investigated by polymerase chain reaction – restriction fragment length polymorphism (PCR-RFLP) technique. Primers sequences, restriction endonuclease enzymes and the size of restriction fragments obtained from PCR-RFLP reaction are shown in Table 1. Amplification was performed in a PTC-200 Thermal Cycler (MJ Research, Inc. Waltham, MA). Genomic DNA (300ng) was amplified using the following conditions: initial denaturation at 95°C for 6 min, followed by 35 cycles at 94°C for 30s, annealing at 60°C for 30s and extension at 72°C for 1 minute. The final extension step was at 72°C for 7 minutes. The resulting DNA fragments were separated by electrophoresis on 2.5 % agarose gel.

Statistical Analysis

Data analysis was performed using the SPSS Statistics 23.0 software (IBM Corp., Armonk, NY, USA). All tests were two-sided and the p value <0.050 indicated statistical significance. Deviation from Hardy-Weinberg equilibrium (HWE) expectations was evaluated by χ^2 goodness-of-fit test. The means of variables were compared by a student's t test (continuous variables) or χ^2 test of independence (discrete variables). The correlations of variables were computed with the Spearman's rank correlation coefficient. ANCOVA (analysis of covariance) was used to assess the effect of RNLS genotypes on plasma RNLS level after adjustment for potentially confounding effect of age, gender, BMI, hemoglobin and albumin level, the presence of hypercholesterolemia and RRF. For post-hoc analyses Sidak's correction test was performed.

TABLE 1. Primers sequences, restriction endonuclease enzymes and size of restriction fragments obtained from PCR-RFLP reaction.

Gene variants	Primer sequence (5'-3')	Restriction enzyme	Fragment sizes	
			Undigested (A allele)	Polymorphic variant (G allele)
Rs10887800	F: CAGGAAAGAAAGAGTTGACAT R: AAGTTGTTCCAGCTACTGT	Pst I	554 bp	415+139 bp
Rs2576178	F: AGCAGAGAAGCAGCTTAACCT R: TTATCTGCAAGTCAGCGTAAC	Msp I	525 bp	423+102 bp

TABLE 2. Demographic and clinical characteristics of studied subgroups.

Characteristics	Arterial hypertension		p value*	Coronary artery disease		p value*
	HY+	HY-		CAD+	CAD-	
	(n=259)	(n=50)		(n=107)	(n=202)	
Age (years)	64.01 $\pm$ 14.04	64.62 $\pm$ 14.31	>0.050	69.61 $\pm$ 10.51	61.20 $\pm$ 14.83	<0.001
Gender						
Male, n (%)	138 (53.3)	19 (38)	<0.050	64 (59.81)	93 (46.03)	<0.001
Female, n (%)	121 (46.7)	31 (62)		43 (40.19)	109 (53.97)	<0.001
Laboratory parameters						
BMI (kg/m ²)	25.83 $\pm$ 5.28	25.44 $\pm$ 5.55	>0.050	27.47 $\pm$ 5.62	24.87 $\pm$ 4.93	<0.001
Hemoglobin (g/dl)	10.54 $\pm$ 1.41	10.95 $\pm$ 1.43	>0.050	10.6 $\pm$ 1.3	11.0 $\pm$ 1.45	<0.050
Albumin (g/dl)	3.94 $\pm$.38	3.97 $\pm$.42	>0.050	3.86 $\pm$.36	3.98 $\pm$.39	<0.050
Hyperlipidemia, n (%)	130 (50.8)	22 (44)	>0.050	65 (61.3)	87 (43.5)	<0.010
Renalase ($\mu\text{g/mL}$)	33.23 $\pm$ 12.20	35.19 $\pm$ 13.26	>0.050	33.95 $\pm$ 12.74	33.33 $\pm$ 12.21	>0.050
Dialysis vintage (yrs)	5.93 $\pm$ 5.72	8.48 $\pm$ 8.53	<0.050	6.01 $\pm$ 6.16	6.52 $\pm$ 6.40	>0.050
Smoking, n (%)	43 (16.6)	5 (10)	>0.050	21 (19.6)	27 (13.4)	>0.050
Alcoholism, n (%)	7 (2.7)	1 (2)	>0.050	2 (1.9)	6 (3)	>0.050
CVD in FH, n (%)	39 (15.1)	3 (6)	>0.050	21 (19.6)	21 (10.4)	<0.010

Continuous variables are presented as means $\pm$ SD. Discrete variables are presented as numbers and percentages (in parentheses). HY – arterial hypertension, CAD – coronary artery disease, BMI – Body Mass Index, CVD – cardiovascular disease, FH – family history. * t-student or χ^2 tests.

RESULTS

Characteristics of the study population

Clinical and demographic characteristics of the study participants are summarized in Table 2. Compared with HY- group, hypertensive patients were more frequently male (53.3% vs 38%) and had shorter dialysis vintage (5.93±5.72 vs 8.48±8.53 years). Compared with CAD-, patients with CAD were older (69.61±10.51 vs 61.20±14.83 years) and more often male. They had lower hemoglobin and albumin level and higher prevalence of hyperlipidemia. CAD+ patients were also more likely to have a positive family history of CVDs and higher BMI value. Mean plasma RNLS concentration in the study cohort was 33.54±12.37 µg/mL. There were no differences in plasma RNLS level neither between patients with and without HY (33.23±12.20 µg/mL vs 35.19±13.26 µg/mL, respectively), $p>0.050$ nor between patients with and without CAD (33.95±12.74 µg/mL vs 33.33±12.21 µg/mL, respectively) $p>0.050$.

Effect of RNLS gene polymorphisms (rs1088700 and rs2576178) on plasma renalase level depending on the comorbidity

Genotype distribution of studied polymorphisms was consistent with Hardy-Weinberg equilibrium (rs10887800 SNP: $\chi^2=0.18$, $p=0.669$ for CAD+, $\chi^2=1.80$, $p=0.180$ for CAD-, $\chi^2=0.04$, $p=0.833$ for HY+, $\chi^2=2.16$, $p=0.142$ for HY-; rs2576178 SNP: $\chi^2=0.11$, $p=0.735$ for CAD+, $\chi^2=0.02$, $p=0.888$ for CAD-, $\chi^2=0.10$, $p=0.755$ for HY+, $\chi^2=0.01$, $p=0.938$ for HY-). As shown in Table 3, regarding rs10887800 polymorphism, hypertensive AA homozygotes had significantly lower plasma RNLS level (28.93±9.94 µg/mL) compared to AG (34.06±12.79 µg/mL) and GG carriers (36.54±12.01 µg/mL), $p=0.002$. Among CAD patients no differences in plasma RNLS concentrations between rs10887800AA, AG and GG carriers were observed, $p=0.615$. For the rs2576178 variant, both HY and CAD participants did not differ in terms of plasma RNLS levels with regard to the particular genotypes, $p>0.050$.

Correlation between RNLS level and CVRFs

Plasma RNLS level was significantly higher in anuric patients compared to those with preserved RRF (38.62±11.59 µg/mL vs 27.23±10.26 µg/mL, $p<0.001$) (Figure 1), but did not correlate with patient's age, BMI, albumin, glucose and hemoglobin levels. No difference in RNLS concentration between males and females (33.54±12.57 µg/mL vs 33.54±12.20 µg/mL, respectively), $p=1.000$ was found. Plasma RNLS concentration correlated neither with SBP ($r=-0.110$, $p=0.060$) nor with DBP ($r=-0.080$, $p=0.200$). There was also no difference in RNLS level between patients with and without hypercholesterolemia (34.79±13.44 µg/mL vs 32.51±11.34 µg/mL, $p=0.133$) and between smoking and no-smoking individuals (33.24±12.14 µg/mL vs 32.51±11.34 µg/mL, $p=.465$). Finally, plasma RNLS correlated neither with hemodialysis adequacy measured by spKt/Vurea ($r=-0.140$, $p=0.239$) nor with dialysis vintage ($r=0.226$, $p=0.256$).

DISSCUSSION

In the present study, which is a continuation and extension of our previous research, we demonstrated for the first time that the effect of rs10887800 RNLS gene polymorphism (located in intron 6) on plasma RNLS level in HD patients

is co-dependent on the presence of comorbid disorders. Hypertensive rs10887800AA carriers had significantly lower RNLS concentration compared to those with AG and GG genotypes. However, similar associations were not observed in CAD+ subgroup. Therefore, we can assume that the impact of rs10887800 variant on plasma RNLS level, previously reported by us in patients undergoing HD, was due to high prevalence of hypertensive participants in the study cohort [9].

The obtained results suggest that rs10887800 RNLS polymorphism can affect the risk of HY by the modulation of plasma RNLS level. However, our findings should be interpreted with caution since the pathophysiological role of RNLS in HY remains controversial. First experimental studies demonstrated decreased plasma RNLS level in hypertensive rats after 5/6 nephrectomy [10]. Recombinant RNLS infusion lowered blood pressure [11] and it was through metabolizing circulating catecholamines [12]. Human research on uremic populations brought discrepant results. In the present study we did not observe differences in plasma RNLS level between HY+ and HY- subgroups. Similar findings were obtained in other studies on patients undergoing both hemodialysis [13] and peritoneal dialysis [14]. Furthermore, no association between plasma RNLS level and left ventricular hypertrophy (LVH), a cardiac consequence of inadequate HY control, was observed [15].

TABLE 3. Plasma renalase (RNLS) level according to RNLS genotypes in concomitant comorbidities subgroups.

Concomitant disease	Renalase gene variant	Genotypes			p value*
		AA	AG	GG	
HY (n=259)	Rs2576178 (147/95/17)	32.70±12.83	33.91±11.06	34.32±12.98	0.358
	Rs10887800 (69/131/59)	28.93a±9.96	34.06b±12.79	36.54b±12.01	0.002
CAD (n=107)	Rs2576178 (54/43/10)	32.30±13.17	35.18±12.24	38.21±12.18	0.728
	Rs10887800 (24/51/32)	31.52±10.95	34.75±13.37	34.44±13.10	0.615

HY – arterial hypertension, CAD – coronary artery disease. RNLS levels presented as means±SD. *ANCOVA (analysis of covariance) assessing the effect of RNLS genotypes on RNLS level after adjustment for potentially confounding effect of age, gender, BMI, hemoglobin and albumin level, the presence of hypercholesterolemia and residual renal function.

FIGURE 1. The correlation between plasma renalase level and the presence of preserved residual renal function.

Oppositely, Dziedzic et al. demonstrated a positive correlation between plasma RNLS and mean arterial pressure (MAP) in HD cohort [16].

Our study confirmed literature data that plasma RNLS level is elevated in anuric patients compared to those with preserved RRF, which may be due to its impaired clearance. Importantly, loss of diuresis is a well recognized CVD mortality predictor in ESKD patients [17]. Furthermore, we did not observe correlation between plasma RNLS levels and known CVRFs. On the contrary, Zbroch et al. demonstrated a link between plasma RNLS and age in dialyzed individuals. However, the authors concluded that elevated plasma RNLS in older patients could be due to impaired kidney function and high burden of CVDs rather than age itself [18].

The results obtained in the current study are novel. As far as the authors know, no other papers concerning the effect of RNLS polymorphisms on plasma renalase level were published. Furthermore, there are hardly any studies on the mechanism through which RNLS variants affect CVDs risk [19].

Our study has some limitations which have to be pointed out. First, all participants were Caucasian, therefore the experiment should be replicated on different ethnic groups. Secondly, plasma RNLS activity, tissues expression and RNLS concentrations in urine and dialysis fluid were not assessed. Finally, the correlation analyses between *RNLS* SNPs, CVRFs and catecholamines level should be performed. However, this will be the subject of ongoing studies.

CONCLUSIONS

Obtained results extend our previous findings and indicate for the first time that the effect of rs10887800 *RNLS* gene polymorphism on plasma RNLS level in HD patients is co-dependent on the presence of comorbid disorders. Rs10887800 variant modifies the level of plasma RNLS in hypertensive HD patients but not in those with CAD. Plasma RNLS level is elevated in anuric patients and does not correlate with known CVRFs. The study provides thus a new insight into the potential mechanisms through which *RNLS* gene variants modulate the risk of CVDs in uremic patients.

REFERENCES

1. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med*. 2004;351:1296-305.
2. Burmeister JE, Mosmann CB, Costa VB, et al. Prevalence of cardiovascular risk factors in hemodialysis patients – The CORDIAL Study. *Arq Bras Cardiol*. 2014;102:473-80.
3. Weiner DE, Tabatabai S, Tighiouart H, et al. Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. *Am J Kidney Dis*. 2006;48:392-401.
4. Longenecker JC, Coresh J, Powe NR, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE Study. *J Am Soc Nephrol*. 2002;13:1918-27.
5. Desir GV. Regulation of blood pressure and cardiovascular function by renalase. *Kidney Int*. 2009;76:366-70.
6. Stec A, Semczuk A, Furmaga J, et al. Polymorphism of the renalase gene in end-stage renal disease patients affected by hypertension. *Nephrol Dial Transplant*. 2012;27:4162-6.
7. Stec A, Ksiazek A, Buraczynska M. Rs10887800 renalase gene polymorphism is associated with an increased risk of coronary artery disease in hemodialyzed patients. *Int Urol Nephrol*. 2016;48:871-6.
8. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. *Am J Kidney Dis*. 2005;45(4 Suppl 3):S1-153.
9. Stec A. Rs10887800 renalase gene polymorphism influences the level of circulating renalase in patients undergoing hemodialysis but not in healthy controls. *BMC Nephrol*. 2017;18:118.
10. Desir GV. Renalase deficiency in chronic kidney disease, and its contribution to hypertension and cardiovascular disease. *Curr Opin Nephrol Hypertens*. 2008;17:181-5.
11. Baraka A, El Ghotny S. Cardioprotective effect of renalase in 5/6 nephrectomized rats. *J Cardiovasc Pharmacol Ther*. 2012;17:412-6.
12. Desir GV, Tang L, Wang P, et al. Renalase Lowers Ambulatory Blood Pressure by Metabolizing Circulating Adrenaline. *J Am Heart Assoc*. 2012;1:e002634.
13. Zbroch E, Malyszko J, Malyszko JS, et al. Renalase, a novel enzyme involved in blood pressure regulation, is related to kidney function but not to blood pressure in hemodialysis patients. *Kidney Blood Press Res*. 2012;35:395-9.
14. Zbroch E, Malyszko J, Malyszko J, et al. Renalase in peritoneal dialysis patients is not related to blood pressure, but to Dialysis Vintage. *Perit Dial Int*. 2012;32:348-51.
15. Oguz EG, Gursoy GK, Yayar O, et al. Increased serum renalase in hemodialysis patients: is it related to left ventricular hypertrophy? *Ren Fail*. 2016;38:1180-6.
16. Dziedzic M, Petkowicz B, Bednarek-Skublewska A, et al. Relationship between renalase and N-terminal pro-B-type natriuretic peptide (NT pro-BNP) in haemodialysis patients. *Ann Agric Environ Med*. 2014;21:132-5.
17. Shemin D, Bostom AG, Laliberty P, et al. Residual renal function and mortality risk in hemodialysis patients. *Am J Kidney Dis* 2001;38:85-90.
18. Zbroch E, Musialowska D, Koc-Zorawska E, Malyszko J. Age influence on renalase and catecholamines concentration in hypertensive patients, including maintained dialysis. *Clin Interv Aging*. 2016;11:1545-50.
19. Manning AK, Hivert MF, Scott RA, et al. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. *Nat Genet* 2012;44:659-69.

Corresponding author

Dr Anna Steć

Department of Nephrology, Medical University of Lublin

8 Jaczewskiego St., 20-954 Lublin, Poland

E-mail: annastec@poczta.onet.pl

tel: +48 (81) 724 47 04

fax: +48 (81) 724 45 37